Cultured meat is already available in a handful of countries, though most people can’t walk into a grocery store and buy it yet. As of mid-2025, regulatory approvals exist in the United States, Singapore, Israel, and Australia/New Zealand, but commercial availability remains extremely limited. For most of the world, the realistic timeline for widespread access is still several years away, held back by production costs that need to drop dramatically before cultured meat can compete with conventional options.
Where Cultured Meat Is Approved Today
The first country to allow sales was Singapore, which approved cultured chicken from Good Meat back in 2020. The U.S. followed in June 2023, when both Upside Foods and Good Meat received final approval from the USDA to sell cell-cultivated chicken. That approval came after completing premarket consultations with the FDA, receiving facility inspections, and getting label approval earlier that spring.
In January 2024, Israel became the first country to approve cultured beef. The Israeli Ministry of Health cleared a product from Aleph Farms after a thorough safety evaluation, making Israel a global leader in this space. The country has backed the industry with dedicated institutions and significant investment. Then in June 2025, Australia and New Zealand updated their food standards code to allow cell-cultured quail as a novel food ingredient.
Despite these approvals, none of these products are widely sold. In the U.S., cultured chicken has appeared only at a small number of restaurants. You cannot yet find it in supermarkets, and no company has scaled production enough to supply a mass retail market.
Why It’s Still So Expensive
The core barrier is cost, and the biggest cost driver is the liquid nutrient mixture (called growth media) that cells need to multiply. This media alone accounts for at least 50% of variable operating costs in cultivated meat production. Within that media, specialized proteins called growth factors are responsible for the bulk of the expense. In some formulations, just two growth factor proteins account for nearly 98% of the total media cost.
The original proof-of-concept burger, produced in 2013, cost over $300,000. Prices have fallen enormously since then, but they’re still nowhere near competitive with conventional meat. The industry has moved away from using fetal bovine serum, an animal-derived ingredient that raised both ethical and cost concerns, replacing it with serum-free alternatives. One company, Believer Meats, has demonstrated that serum-free media can be produced for as little as $0.63 per liter by optimizing ingredient concentrations and swapping out expensive components. That’s a major step, but scaling this across an entire production facility that can output thousands of pounds of meat is a different challenge entirely.
Researchers at Tufts University have been working on engineering cell lines that need fewer of these costly growth factors to survive and multiply. The concept dates back to the early 1990s, when scientists first showed that genetically modifying cells could remove their dependence on expensive serum. Recent work has built on this approach, and if it translates to commercial-scale production, it could cut the dominant cost category by a significant margin.
Europe Is Still Years Away
If you’re in Europe, the wait will be longer. The European Food Safety Authority (EFSA), which must evaluate any novel food before it can be sold in the EU, has not yet received a single application for cultured meat. EFSA has stated publicly that it expects applications “in the coming months and years” and is preparing its scientific framework, but the evaluation process itself typically takes 18 months or more once an application is submitted. Realistically, EU consumers are unlikely to see approved products before 2027 or 2028 at the earliest, and that assumes companies submit applications soon.
The UK Is Moving Faster Than Europe
The United Kingdom, no longer bound by EU food regulations, has taken a notably different approach. The Food Standards Agency (FSA) launched a “Sandbox Programme” specifically designed to fast-track regulatory knowledge around cell-cultivated products. This program, funded by the Department of Science and Technology, gives companies clearer guidance on how to demonstrate their products are safe, reducing uncertainty and wait times. The FSA published its first safety guidance for cell-cultivated products and plans to release additional guidance throughout 2026. While no products are approved for sale in the UK yet, the regulatory path is more defined than in the EU, and approvals could come sooner.
What a Realistic Timeline Looks Like
The honest answer depends on where you live and what you mean by “available.” If you mean legally approved somewhere on Earth, cultured meat is available now. If you mean something you can reliably order at a restaurant in the U.S., Singapore, or Israel, that’s a narrow possibility today, limited to specific locations and products. If you mean buying it at a reasonable price from a grocery store, that’s likely still 5 to 10 years out for most consumers.
The path from approval to affordability requires solving the production cost problem at industrial scale. Companies need to build bioreactors large enough to produce meaningful quantities, source affordable growth media consistently, and achieve the kind of volume that brings per-unit costs down. Several companies have announced plans for large-scale production facilities, but construction and commissioning take years.
Price parity with conventional meat is the milestone that matters most for mainstream adoption. Current estimates vary widely, but most industry analysts place that target somewhere in the late 2020s to early 2030s for initial products like ground meat or chicken, with whole-cut products like steaks taking longer. The trajectory is real, with costs falling by orders of magnitude over the past decade, but the final stretch from “expensive novelty” to “competitive grocery item” involves the hardest scaling challenges the industry has yet faced.